Ibandronic Acid Sandoz

RSS

ibandronic acid

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Ibandronic Acid Sandoz. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ibandronic Acid Sandoz.

This EPAR was last updated on 19/10/2016

Authorisation details

Product details
Name
Ibandronic Acid Sandoz
Agency product number
EMEA/H/C/002367
Active substance
ibandronic acid
International non-proprietary name (INN) or common name
ibandronic acid
Therapeutic area (MeSH)
  • Breast Neoplasms
  • Neoplasm Metastasis
  • Fractures, Bone
Anatomical therapeutic chemical (ATC) code
M05BA06
GenericGeneric

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Sandoz GmbH
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
26/07/2011
Contact address
Biochemiestrasse 10
6250 Kundl
Austria

Product information

21/07/2016 Ibandronic Acid Sandoz - EMEA/H/C/002367 - IB/0019

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Prevention of skeletal events

Therapeutic indication

Ibandronic acid Sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

Assessment history

How useful was this page?

Add your rating